The science
Melanotan 2 Research: Mechanism, Studies, and What They Measured
One non-selective peptide, several receptors, several effects — traced through the pigmentation, appetite, and sexual-function literature.
Before the details
Here is the Melanotan 2 research in plain terms. The peptide works by switching on a family of cell receptors called melanocortin receptors. There are five of them, in different places. The skin one (MC1R) makes pigment. The brain ones (mainly MC4R) control hunger and sexual function. Because Melanotan 2 hits all of them, it does several things at once.
The strongest human evidence is small and old: a three-person tanning pilot and a ten-person erectile-dysfunction study, both from the 1990s. Most of the rest is rodent work — mice and rats — showing the same appetite and pigment effects, plus newer studies on brain, behavior, and even nerve repair. There is no large human trial. So the picture is: a clear, repeatable mechanism, real but tiny human data, a lot of animal data, and big unanswered questions about long-term safety. Every number below is tied to a specific study.
The pigmentation pathway: MC1R to melanin
Melanotan 2's tanning effect runs through a well-characterized cascade. The peptide binds MC1R on melanocytes (pigment cells), which activates adenylyl cyclase and raises intracellular cAMP (a second-messenger molecule that relays the signal inside the cell) [13]. Raised cAMP activates protein kinase A, which phosphorylates the transcription factor CREB, which in turn upregulates MITF — the master regulator of the melanocyte lineage [13]. MITF then drives expression of tyrosinase and related enzymes that synthesize melanin, shifting output toward the darker, more photoprotective eumelanin [13].
Crucially, this happens without UV exposure, because the peptide activates the receptor directly rather than via sun damage [2]. A human study of the linear analog showed pigmentation persists for weeks after the peptide has cleared, because melanin synthesis continues downstream of the brief receptor signal [14]. The original Arizona work even framed the compound as a potential skin-cancer chemopreventive on this basis [4].
Melanotan II in the human studies
Human data on Melanotan II is limited but specific. The 1996 pilot Phase I study (single-blind, placebo-controlled, three healthy men, subcutaneous doses escalated from 0.01 to 0.025–0.03 mg/kg every other weekday for two weeks — a study-design fact, not a dosing recommendation) increased facial, upper-body, and buttock pigmentation in two of three subjects after only five low doses, with spontaneous erections lasting one to five hours and mild nausea; dose-limiting somnolence appeared at the highest dose [2].
The 1998 double-blind crossover study in ten men with psychogenic erectile dysfunction used 0.025 mg/kg subcutaneously and produced clinically apparent erections in eight of ten men, with mean rigidity duration of 38.0 minutes versus 3.0 minutes on placebo (p=0.0045) and transient, self-resolving nausea, stretching, and yawning [3]. No Phase 2 or Phase 3 trial of Melanotan 2 itself has ever been completed [4].
The MC4R side: appetite, energy, and the brain
The appetite effect is mediated centrally through MC4R and MC3R. In male C57BL/6J mice, bilateral microinjection of Melanotan 2 into the nucleus accumbens (a reward-and-motivation brain region) at 0.1–1 nmol per side significantly decreased food consumption in both home-cage and operant paradigms and reduced the motivation to work for food — without producing conditioned taste aversion or changing metabolic rate [39]. In Wistar rats on free-choice diets, central Melanotan 2 suppressed calorie intake most strongly in animals eating a high-saturated-fat diet and preferentially cut the fat component, leading the authors to conclude that dietary fat content, not the degree of obesity, governs sensitivity of the melanocortin feeding response [40].
The same central melanocortin signaling reaches sexual-function and social circuits. In a randomized functional-MRI study, MC4R agonism with the Melanotan 2-derived analog bremelanotide increased self-reported sexual desire and altered insula activation during erotic cues in women with hypoactive sexual desire disorder [7].
Beyond pigment and appetite: the wider record
More recent and exploratory work keeps widening the picture. A 2026 case report documented reversible oral-mucosal pigmentation in a man who self-administered Melanotan 2 (400 µg subcutaneously every other day for 64 days; 12.8 mg cumulative — a study-reported exposure, not a dosing instruction): brown pigment developed on the gingiva and buccal mucosa, with the buccal pigment beginning to fade by 28 days after stopping while gingival pigment persisted at three months [41].
A broad review of alpha-MSH biology provides the endogenous-ligand context — the melanocortin system, the MC1R-driven melanogenesis pathway, and the clinical relevance of melanocortin signaling — against which all synthetic analogs, Melanotan 2 included, act [13]. The recurring theme across the literature is that Melanotan 2 is a powerful, non-selective probe of a multi-tasking receptor family: useful for understanding melanocortin biology, and exactly that breadth is what makes it hard to use safely outside a lab.